SC
MYGN icon

Sculptor Capital’s Myriad Genetics MYGN Stock Holding History

Sculptor Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,800
Closed -$250K – 404
2015
Q4 		$250K Hold
5,800
– – ﹤0.01% 318
2015
Q3 		$217K Hold
5,800
– – ﹤0.01% 347
2015
Q2 		$197K Hold
5,800
– – ﹤0.01% 383
2015
Q1 		$205K Sell
5,800
-7,400
-56% -$265K ﹤0.01% 373
2014
Q4 		$450K Buy
+13,200
New +$468K ﹤0.01% 681

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Sculptor Capital's MYGN Position: Q1 2016 in Review

Sculptor Capital sold out of Myriad Genetics (MYGN) in Q1 2016, closing a stake of 5,800 shares — an estimated $250K sold.

Sculptor Capital first reported a position in MYGN in Q4 2014 and held it in 5 quarters. The position peaked at $450K in Q4 2014. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2016.

  • Sculptor Capital reported no remaining Myriad Genetics position as of Q1 2016 after selling out during the quarter.
  • Sculptor Capital sold 5,800 Myriad Genetics shares in Q1 2016, an estimated $250K.
  • Sculptor Capital first reported a position in Myriad Genetics in Q4 2014 and held it in 5 quarters.
  • Sculptor Capital's Myriad Genetics position peaked at $450K in Q4 2014.
  • 233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2016.

Based on Sculptor Capital's 13F filing for Q1 2016, filed 16 May 2016.